Cantargia AB Company Description

Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases.

The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis.

It also develops CANxx, an IL1RAP-based antibody platform. The company has collaboration agreements with Patheon Biologics B.V.

and BioWa Inc. for the manufacture and production of CAN04; and GEICAM, Spanish breast cancer group.

Cantargia AB (publ) was incorporated in 2009 and is based in Lund, Sweden.